Abstract
Summary
Butalbital is a barbiturate with an intermediate duration of action. Butalbital is often combined with other medications, such as paracetamol (acetaminophen) or aspirin, for the treatment of pain and headache.
LPI (LP Information)' newest research report, the “Butalbital Industry Forecast” looks at past sales and reviews total world Butalbital sales in 2022, providing a comprehensive analysis by region and market sector of projected Butalbital sales for 2023 through 2029. With Butalbital sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Butalbital industry.
This Insight Report provides a comprehensive analysis of the global Butalbital landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Butalbital portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Butalbital market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Butalbital and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Butalbital.
The global Butalbital market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Butalbital is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Butalbital is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Butalbital is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Butalbital players cover Alvogen, Mayne Pharma, Teva, Novartis and SUNRISEPHARMA, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Butalbital market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Tablets
Capsules
Segmentation by application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alvogen
Mayne Pharma
Teva
Novartis
SUNRISEPHARMA
Key Questions Addressed in this Report
What is the 10-year outlook for the global Butalbital market?
What factors are driving Butalbital market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Butalbital market opportunities vary by end market size?
How does Butalbital break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Butalbital Industry Forecast” looks at past sales and reviews total world Butalbital sales in 2022, providing a comprehensive analysis by region and market sector of projected Butalbital sales for 2023 through 2029. With Butalbital sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Butalbital industry.
This Insight Report provides a comprehensive analysis of the global Butalbital landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Butalbital portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Butalbital market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Butalbital and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Butalbital.
The global Butalbital market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Butalbital is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Butalbital is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Butalbital is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Butalbital players cover Alvogen, Mayne Pharma, Teva, Novartis and SUNRISEPHARMA, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Butalbital market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Tablets
Capsules
Segmentation by application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alvogen
Mayne Pharma
Teva
Novartis
SUNRISEPHARMA
Key Questions Addressed in this Report
What is the 10-year outlook for the global Butalbital market?
What factors are driving Butalbital market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Butalbital market opportunities vary by end market size?
How does Butalbital break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Butalbital Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Butalbital by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Butalbital by Country/Region, 2018, 2022 & 2029
2.2 Butalbital Segment by Type
2.2.1 Tablets
2.2.2 Capsules
2.3 Butalbital Sales by Type
2.3.1 Global Butalbital Sales Market Share by Type (2018-2023)
2.3.2 Global Butalbital Revenue and Market Share by Type (2018-2023)
2.3.3 Global Butalbital Sale Price by Type (2018-2023)
2.4 Butalbital Segment by Application
2.4.1 Retail Pharmacies
2.4.2 Hospital Pharmacies
2.4.3 Online Pharmacies
2.5 Butalbital Sales by Application
2.5.1 Global Butalbital Sale Market Share by Application (2018-2023)
2.5.2 Global Butalbital Revenue and Market Share by Application (2018-2023)
2.5.3 Global Butalbital Sale Price by Application (2018-2023)
3 Global Butalbital by Company
3.1 Global Butalbital Breakdown Data by Company
3.1.1 Global Butalbital Annual Sales by Company (2018-2023)
3.1.2 Global Butalbital Sales Market Share by Company (2018-2023)
3.2 Global Butalbital Annual Revenue by Company (2018-2023)
3.2.1 Global Butalbital Revenue by Company (2018-2023)
3.2.2 Global Butalbital Revenue Market Share by Company (2018-2023)
3.3 Global Butalbital Sale Price by Company
3.4 Key Manufacturers Butalbital Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Butalbital Product Location Distribution
3.4.2 Players Butalbital Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Butalbital by Geographic Region
4.1 World Historic Butalbital Market Size by Geographic Region (2018-2023)
4.1.1 Global Butalbital Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Butalbital Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Butalbital Market Size by Country/Region (2018-2023)
4.2.1 Global Butalbital Annual Sales by Country/Region (2018-2023)
4.2.2 Global Butalbital Annual Revenue by Country/Region (2018-2023)
4.3 Americas Butalbital Sales Growth
4.4 APAC Butalbital Sales Growth
4.5 Europe Butalbital Sales Growth
4.6 Middle East & Africa Butalbital Sales Growth
5 Americas
5.1 Americas Butalbital Sales by Country
5.1.1 Americas Butalbital Sales by Country (2018-2023)
5.1.2 Americas Butalbital Revenue by Country (2018-2023)
5.2 Americas Butalbital Sales by Type
5.3 Americas Butalbital Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Butalbital Sales by Region
6.1.1 APAC Butalbital Sales by Region (2018-2023)
6.1.2 APAC Butalbital Revenue by Region (2018-2023)
6.2 APAC Butalbital Sales by Type
6.3 APAC Butalbital Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Butalbital by Country
7.1.1 Europe Butalbital Sales by Country (2018-2023)
7.1.2 Europe Butalbital Revenue by Country (2018-2023)
7.2 Europe Butalbital Sales by Type
7.3 Europe Butalbital Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Butalbital by Country
8.1.1 Middle East & Africa Butalbital Sales by Country (2018-2023)
8.1.2 Middle East & Africa Butalbital Revenue by Country (2018-2023)
8.2 Middle East & Africa Butalbital Sales by Type
8.3 Middle East & Africa Butalbital Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Butalbital
10.3 Manufacturing Process Analysis of Butalbital
10.4 Industry Chain Structure of Butalbital
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Butalbital Distributors
11.3 Butalbital Customer
12 World Forecast Review for Butalbital by Geographic Region
12.1 Global Butalbital Market Size Forecast by Region
12.1.1 Global Butalbital Forecast by Region (2024-2029)
12.1.2 Global Butalbital Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Butalbital Forecast by Type
12.7 Global Butalbital Forecast by Application
13 Key Players Analysis
13.1 Alvogen
13.1.1 Alvogen Company Information
13.1.2 Alvogen Butalbital Product Portfolios and Specifications
13.1.3 Alvogen Butalbital Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Alvogen Main Business Overview
13.1.5 Alvogen Latest Developments
13.2 Mayne Pharma
13.2.1 Mayne Pharma Company Information
13.2.2 Mayne Pharma Butalbital Product Portfolios and Specifications
13.2.3 Mayne Pharma Butalbital Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Mayne Pharma Main Business Overview
13.2.5 Mayne Pharma Latest Developments
13.3 Teva
13.3.1 Teva Company Information
13.3.2 Teva Butalbital Product Portfolios and Specifications
13.3.3 Teva Butalbital Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Teva Main Business Overview
13.3.5 Teva Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Butalbital Product Portfolios and Specifications
13.4.3 Novartis Butalbital Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 SUNRISEPHARMA
13.5.1 SUNRISEPHARMA Company Information
13.5.2 SUNRISEPHARMA Butalbital Product Portfolios and Specifications
13.5.3 SUNRISEPHARMA Butalbital Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 SUNRISEPHARMA Main Business Overview
13.5.5 SUNRISEPHARMA Latest Developments
14 Research Findings and Conclusion